Published on ADDitudeMag.com

Drug Maker Shire Expands to Europe

The maker of Vyvanse has a new presence in European markets.


Pharmaceutical company Shire, maker of Vyvanse, has acquired rights to Equasym, a European medication used for the treatment of attention deficit hyperactivity disorder (ADD ADHD). Shire will continue to market Equasym within Europe, but it is not currently approved within the U.S. and Canada. Shire is also testing Vyvanse (now in Phase 3 trials) for approval in Europe.

Says Michael Cola, president of Shire’s Specialty Pharmaceuticals business: “Our expertise and portfolio of ADHD products will provide a strong foundation from which we can offer innovative treatments for adults and children with ADHD.”

Read more from Shire.


Copyright © 1998 - 2013 New Hope Media LLC. All rights reserved. Your use of this site is governed by our
Terms of Service (http://www.additudemag.com/adhd/terms.html) and
Privacy Policy (http://www.additudemag.com/adhd/privacy.html).
ADDitude does not provide medical advice, diagnosis, or treatment. The material on this web site is provided for educational purposes only.
See additional information at http://www.additudemag.com/adhd/disclaimer.html
New Hope Media, 39 W. 37th Street, 15th Floor, New York, NY 10018

Adult ADHD | Parenting ADHD Children | ADHD Treatment | School & Learning Disabilities | About ADHD | ADHD Resources | ADHD Community
Source: Drug Maker Shire Expands to Europe